Predictive Factors and Clinical Events Associated with Edoxaban Interruption and Heparin Bridging Strategy: EMIT-AF/VTE.

Journal Information

Full Title: Clin Appl Thromb Hemost

Abbreviation: Clin Appl Thromb Hemost

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest Disclosure: AS reports consultancy, speaking payments, and travel support from Bayer; Daiichi Sankyo, Inc.; Boehringer Ingelheim; and Pfizer. CC is a full-time employee and holds stock options for Daiichi Sankyo, Inc. PC reports grants or contracts from Daiichi Sankyo, Inc.; consulting fees from Bayer, Daiichi Sankyo, Inc., and Sanofi; travel support from Amgen; and participation on a data safety monitoring board or advisory board for Bayer and Daiichi Sankyo, Inc. CvH reports consulting fees from Artcline GmbH, Mitsubishi Pharma, Daiichi Sankyo, Inc., Novo Nordisk Pharma, and Shionogi Pharma; speaker bureau payments from Artcline GmbH, CSL Behring, Daiichi Sankyo, Inc., HICC GbR, Mitsubishi Pharma, Novo Nordisk Pharma, Sobi Pharma, and Shionogi Pharma; travel support from Daiichi Sankyo, Inc.; participation on a data safety monitoring board or advisory board for Artcline GmbH; and mandated unpaid guideline writing/participation in guideline writing groups for the German Medical Chamber, the German Society of Anaesthesiology and Intensive Care Medicine, and the European Society of Anaesthesiology and Intensive Care Medicine. MS reports institutional grants from Recor Medical, Inc., Ablative Solutions, Inc., Vascular Dynamics Inc., Applied Therapeutics, and MSD; consulting fees from Recor Medical, Inc., Novartis, Esperion, Daiichi Sankyo, Inc., and Vifor Pharma; and speaker fees from Recor Medical, Inc. and Alnylam. TV reports consulting and speaker bureau fees for Bayer, Boehringer Ingelheim, Pfizer/BMS, Leo Pharma, Sanofi Aventis, and Daiichi Sankyo, Inc.; and travel support from Daiichi Sankyo, Inc. JJ is a full-time employee and holds stock options for Daiichi Sankyo, Inc. MU is a full-time employee and holds stock options for Daiichi Sankyo, Inc."

Evidence found in paper:

"Funding: The author(s) disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Daiichi Sankyo, Inc."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025